Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06050668 · ClinicalTrials.gov registry record · Phase 2

Essential Amino Acid Supplementation for Femoral Fragility Fractures

A Phase 2 study of Muscle Atrophy and Femoral Fracture, sponsored by Michael C Willey.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
2
Study locations

NCT06050668 is a Phase 2 study of Muscle Atrophy and Femoral Fracture that is actively recruiting participants, run by Michael C Willey. The registered enrollment target is 60 participants, above the 44-participant average among 11 other Muscle Atrophy trials with a reported enrollment target (36% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06050668, a Phase 2 study of Muscle Atrophy and Femoral Fracture, is actively recruiting participants, sponsored by Michael C Willey.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary intervention) or 2) EAA-based supplementation.

Conditions Studied

Muscle Atrophy Femoral Fracture Fragility Fracture

Interventions

  • COMBINATION_PRODUCT Essential Amino Acid Supplementation

Study Locations (2)

Iowa

  • University of Iowa Health Care - Iowa City

Oregon

  • Slocum Center for Orthopedics & Sports Medicine - Eugene

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-06-17
Est. Completion 2025-12
Phase Phase 2

Sponsor

Michael C Willey

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06050668

The ClinicalTrials.gov registry entry for NCT06050668 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 44-participant average among 11 other Muscle Atrophy trials with a reported enrollment target (36% higher). The listed sponsor is Michael C Willey, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Muscle Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Essential Amino Acid Supplementation is the first listed.

NCT06050668 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Iowa, Oregon.

Frequently Asked Questions

What is clinical trial NCT06050668 about?

NCT06050668 is a clinical study titled "Essential Amino Acid Supplementation for Femoral Fragility Fractures". This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce musc...

What is the current status of trial NCT06050668?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-06-17. Estimated completion is 2025-12.

What conditions does trial NCT06050668 study?

This clinical trial studies the following conditions: Muscle Atrophy, Femoral Fracture, Fragility Fracture.

What interventions are being tested in trial NCT06050668?

The interventions under investigation include: Essential Amino Acid Supplementation (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06050668?

This trial is sponsored by Michael C Willey, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06050668 being conducted?

This trial has 2 study locations across Iowa, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Muscle Atrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Muscle Atrophy

All registered trials for this condition

Femoral Fracture

All registered trials for this condition

Iowa

All trials with a study site in Iowa

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.